AG
FATE icon

Aperio Group’s Fate Therapeutics FATE Stock Holding History

Aperio Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.25M Buy
13,730
+3,732
+37% +$232K ﹤0.01% 1461
2020
Q3 		$400K Buy
9,998
+1,987
+25% +$69.4K ﹤0.01% 1937
2020
Q2 		$275K Buy
+8,011
New +$239K ﹤0.01% 2064
2019
Q3 		– Sell
-3,911
Closed -$79K – 2460
2019
Q2 		$79K Buy
+3,911
New +$70.5K ﹤0.01% 2448

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Aperio Group's FATE Position: Q4 2020 in Review

Aperio Group increased its Fate Therapeutics (FATE) stake by 37% in Q4 2020, buying an estimated $232K and bringing the position to 13,730 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1461.

Aperio Group first reported a position in FATE in Q2 2019 and has held it in 4 quarters since. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • Aperio Group held 13,730 shares of Fate Therapeutics worth $1.25M as of Q4 2020.
  • Aperio Group bought 3,732 Fate Therapeutics shares in Q4 2020, an estimated $232K.
  • Fate Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1461 holding.
  • Aperio Group first reported a position in Fate Therapeutics in Q2 2019 and has held it in 4 quarters since.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.